Bayer

What Bayer does

Bayer AG is a German multinational life-sciences company founded in 1863 and headquartered in Leverkusen, with three reporting divisions — Pharmaceuticals, Consumer Health, and Crop Science — operating in 80+ countries through 272 fully consolidated companies and employing 88,078 people worldwide as of FY2025. The Pharmaceuticals division sells prescription products across cardiology (Xarelto, Adempas, Aspirin Cardio), women's health (Mirena), oncology (Nubeqa), ophthalmology (Eylea, plus the newly acquired PER-001 via Perfuse Therapeutics), radiology (the newly FDA-approved AMBELVIST contrast agent), and nephrology (Kerendia); revenue is generated through prescription and hospital channels with pricing determined by regulatory approvals and insurance frameworks. Consumer Health distributes 150+ trusted OTC brands — Aspirin, Aleve, Bepanthen, Claritin, Elevit — through retail pharmacy and e-commerce. Crop Science sells high-value seeds (PRECEON, Intacta, XtendiFlex, Plenexos), biotechnology traits, crop protection products, and the FarmRise digital platform (5M+ registered Indian farmers) via agricultural retail networks and direct-to-farmer digital channels.

Bayer's underlying technology stack includes proprietary AI drug-discovery platforms (Enchant and NeuralPLexer, partnered with Iambic Therapeutics), AI-driven genomic selection for crop breeding, computer vision for seed contamination detection, satellite-and-AI precision spraying, and the SOLIDA-1 manufacturing facility at Chempark Leverkusen, which won ISPE Pharma 4.0 and Operational Excellence awards for AI-driven analytics and 70% CO2 reduction via geothermal energy. FY2025 recorded sales were €45.6B with €9.7B EBITDA (-4.5%) and €5.8B in R&D investment; the company is executing the Dynamic Shared Ownership restructuring (introduced January 2024) targeting €2B in organizational savings by 2026. The 2018 $63B Monsanto acquisition delivered the Crop Science franchise but also brought ~100,000+ Roundup-related lawsuits; the U.S. Supreme Court's June 2026 7-2 ruling in Durnell v. Monsanto provides major relief from warning-based claims, though Bayer has set aside nearly $16B for case settlements historically.

Name

Bayer

Legal name

Bayer AG

Website

https://bayer.com

Company type

Public

Founded year

1863

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Bayer AG is a German life-sciences company operating three divisions — Pharmaceuticals, Consumer Health, and Crop Science — across 80+ countries, generating ~€45.6B FY2025 revenue from prescription drugs (Xarelto, Eylea, Nubeqa), OTC consumer brands (Aspirin, Claritin, Aleve), and agricultural seeds and crop protection products.

Ownership category

akta.pro rank

Product category

Life Sciences - Pharmaceuticals & Agriculture

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Prescription pharmaceuticals
• Consumer health products
• Crop protection seeds
• Precision agriculture platforms
• Life sciences manufacturing

Headquarters

HQ city

Leverkusen

HQ country

Germany

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Others, Operations

Revenue model

1. Pharmaceuticals: Prescription pharmaceutical products including Xarelto, Eylea, Nubeqa, Mirena, Adempas, and Aspirin Cardio sold through healthcare providers, hospitals, and pharmacies globally
2. Consumer Health: Over-the-counter consumer health products including Aspirin, Bepanthen, Claritin, Elevit across 150+ trusted brands sold through retail pharmacies and e-commerce
3. Crop Science: High-value seeds, biotechnology traits, crop protection products, and digital farming tools sold to farmers and agricultural distributors worldwide

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Bayer is a life sciences company operating through three divisions: Pharmaceuticals (prescription drugs including Xarelto, Eylea, NUBEQA, Mirena, Adempas, KERENDIA, AMBELVIST for cardiology, oncology, ophthalmology, women's health, and radiology), Consumer Health (OTC brands including Aspirin, Aleve, Bepanthen, Claritin, Elevit sold through retail pharmacies), and Crop Science (high-value seeds, biotechnology traits, crop protection products, and digital farming tools). The company develops and commercializes these products globally across 80+ countries with €45.6 billion in FY 2025 sales, supported by €5.8 billion in annual R&D investment.

Product overview

Bayer operates as a life science company with three main divisions: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division focuses on prescription products in cardiology (Xarelto, Adempas, Aspirin Cardio), women's healthcare (Mirena), oncology (NUBEQA), ophthalmology (Eylea), and radiology (AMBELVIST contrast agent). Consumer Health offers over 150 trusted self-care brands including Aleve, Bepanthen, Claritin, and Elevit for allergy, dermatology, pain relief, and nutrition. Crop Science provides high-value seeds (PRECEON, Intacta, XtendiFlex, Plenexos), innovative crop protection products, and digital farming tools (FarmRise platform) to help farmers produce more while restoring nature. The company is developing additional products including KERENDIA for chronic kidney disease and asundexian for stroke prevention.

Differentiator

Problem solved

Functional benefit

Products and services

• Xarelto (rivaroxaban)
• Eylea (aflibercept)
• NUBEQA (darolutamide)
• Mirena
• Adempas
• Aspirin Cardio
• AMBELVIST (gadoquatrane)
• KERENDIA (finerenone)
• Asundexian
• Aleve
• Bepanthen
• Claritin
• Elevit
• PRECEON
• Intacta
• XtendiFlex
• Plenexos
• FarmRise Digital Platform
• PER-001

Quantifiable outcome

• €45.6 billion in recorded sales for FY 2025
• +4 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature6 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Iambic TherapeuticscoreTechnology or Integration · 22 June 2026Drug discovery collaboration using AI-powered Enchant and NeuralPLexer platforms to identify novel drug entry points and differentiated molecules against hard-to-drug targets in small-molecule discovery. Iambic receives upfront payment plus milestone and royalty payments. Collaboration aims to accelerate typically lengthy drug discovery processes.
• Perfuse TherapeuticscoreStrategic or Co-development Partner · 17 June 2026Bayer completed acquisition paying $300M upfront with total potential value up to $2.45B including success-based milestones. Perfuse developing PER-001, first-in-class sustained-release endothelin receptor antagonist in Phase II for glaucoma and diabetic retinopathy. Operations headquartered in South San Francisco with R&D in Durham, NC.
• Natur-Tec IndiaminorStrategic or Co-development Partner · 16 June 2026MoU to jointly develop biodegradable and compostable seedling cups to replace single-use plastic nursery containers. Combines Bayer's crop science expertise with Natur-Tec's compostable biopolymer technology. Trial runs scheduled in vegetable and fruit nurseries in India with global scaling planned.
• ISSCR (International Society for Stem Cell Research)minorStrategic or Co-development Partner · 15 June 2026Bayer joined as founding member of ISSCR Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development. Initiative brings together academia, industry, and regulatory agencies including AstraZeneca and Weill Cornell Medicine to advance human stem cell-derived models.
• Aphea.BiominorStrategic or Co-development Partner · 10 June 2026Strategic partnership to develop biological pesticides targeting insect pests in agriculture. Leverages Aphea.Bio's R&D pipeline with Bayer's global market reach and product development capacity. Initially focusing on fruit crops (citrus, grapes) before potentially expanding to vegetables and arable crops.
• Tagros Chemicals IndiaminorChannel Partner/ Reseller/ Distributor · 1 January 2026Tagros acquired Bayer's global Flubendiamide insecticide business covering Latin America, Europe, Middle East, Africa, and Asia-Pacific. Brands include BELT, FAME, TIHAN. Represents Bayer's strategic exit from mature molecules.
• Blackford Analysis Ltd.coreStrategic or Co-development Partner · 1 February 2023Acquisition completed February 2023. Blackford provides AI solutions for medical imaging, operating independently as subsidiary while benefiting from Bayer's global infrastructure and resources to advance its technology.
• TargenomixcoreStrategic or Co-development Partner · 10 November 2022Acquisition of German biotech start-up spin-off from Max Planck Institute for Molecular Plant Physiology. Targenomix's systems biology and computational tools support Bayer's crop protection R&D pipeline against climate change and resistance challenges.
• Noria Therapeutics Inc. and PSMA Therapeutics Inc.coreStrategic or Co-development Partner · 7 June 2021Acquisition to expand oncology portfolio of targeted alpha therapies (TATs). Provides rights to differentiated alpha radionuclide investigational compound based on actinium-225 and PSMA-targeting small molecule.
• DKSH HealthcareminorChannel Partner/ Reseller/ DistributorPartnership for commercialization of Bayer cardiovascular products in Malaysia, Philippines, Singapore, and Thailand. DKSH provides end-to-end commercialization platform for rare disease and specialty therapies in Asia-Pacific region.
• MustGrow BiologicsminorChannel Partner/ Reseller/ DistributorEMEA licensing partnership where MustGrow commercializes biological products. Also partnered with Sumitomo for Americas distribution. MustGrow's TerraSante biofertility product now registered in 10 US states under Organic OMRI certification.
• Rud Pedersen ItalyminorStrategic or Co-development PartnerContributed to roundtable discussion on geopolitics of pharmaceuticals and industrial resilience in Rome, bringing together government officials, pharma industry representatives, and academics to discuss supply chain security.
• BASFminorStrategic or Co-development PartnerMajor agricultural company also leveraging AI platforms for breeding, supply chain management, and precision agriculture alongside Bayer in the $180B GM foods market.
• NovartisminorStrategic or Co-development PartnerMarketplace listing and competitive positioning. Novartis leads radioligand therapy with Pluvicto and Lutathera ($2.8B net sales 2024) while Bayer is one of companies entering the space projected to grow from $3.2B to $30B by 2034.

Scale indicators19 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pfizer: Global pharmaceutical major with comparable prescription drug portfolio spanning cardiology, oncology, and vaccines. Closely comparable to Bayer's Pharmaceuticals division in scale, therapeutic breadth, and patent-cliff exposure.
• Roche: Swiss pharmaceutical major with strong oncology, ophthalmology (Lucentis predecessor to Eylea's market), and diagnostics franchises. Directly comparable to Bayer's prescription pharma business, particularly in oncology and ophthalmology where both compete.
• Novartis: Global pharmaceutical major with cardiology, oncology (radioligand therapy leadership via Pluvicto/Lutathera), and ophthalmology (Beovu). Direct competitor in cardiology and oncology; explicitly compared to Bayer in radioligand therapy space.
• Merck & Co. (MSD): U.S. pharmaceutical major with blockbuster oncology (Keytruda) and vaccines franchises. Comparable in scale and therapeutic area breadth, particularly competing with Bayer's oncology pipeline (NUBEQA, Noria TATs).
• Johnson & Johnson: Diversified healthcare major with pharmaceuticals (cardiology, oncology, immunology) and consumer health divisions. Direct peer to Bayer across both pharma and consumer health, and a co-investor in SonoThera alongside Bayer.
• Sanofi: European pharmaceutical major with prescription drugs, vaccines, and consumer healthcare (allergy via Allegra competing with Bayer's Claritin). Comparable in therapeutic breadth and consumer health focus.
• AstraZeneca: Global biopharmaceutical major with oncology, cardiovascular, and respiratory franchises. Co-participant with Bayer in ISSCR stem cell consortium; comparable in cardiology (Brilinta vs. Xarelto) and oncology pipeline depth.
• GSK: British pharmaceutical and consumer healthcare major with vaccines, specialty medicines, and oral health. Comparable to Bayer in its combined pharma + consumer health structure and allergy/respiratory overlap.
• Corteva: U.S. agricultural inputs and seeds company spun out from DowDuPont. Direct competitor to Bayer's Crop Science division in seeds, traits, and crop protection; explicit licensing partner (freedom-to-operate agreement) with Bayer.

Broad incumbents

• BASF: German chemical major with significant agricultural solutions division. Comparable to Bayer's Crop Science segment in crop protection chemistry; also leverages AI platforms for breeding and precision agriculture alongside Bayer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/bayer
• Facebookfacebook.com/Bayer
• LinkedInlinkedin.com/company/bayer
• Instagraminstagram.com/bayer
• YouTubeyoutube.com/user/BayerTVchannel

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries6 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A22 records

Investments22 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bayer